하시모토 갑상선염을 동반한 갑상선유두암에서 BRAFV600E 돌연변이의 임상병리학적 의미
Clinicopathological Implications of the BRAFV600E Mutation in PTC with Concurrent Hashimoto Thyroiditis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: The relationship between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) is still controversial. Some studies suggested that molecular basis of the association between HT and PTC. BRAFV600E mutation is the most common genetic alteration founded in PTC. This study was to determine a role of BRAFV600E mutation in PTC with concurrent HT and their association with other clinicopathological factors. Materials and Methods: We enrolled 452 patients who underwent thyroid surgery between 2009 and 2012 for classical PTC. The status of BRAFV600E mutation was evaluated by direct sequencing. HT was defined as presence of lymphocytic thyroiditis in pathology or positive serum anti-thyroid peroxidase antibody. Results: Total 139 patients (30%) with PTC had coexistence HT. HT was significantly associated female (p=0.006), and younger age (p=0.045). BRAFV600E mutation was confirmed in 264 patients (58%). The frequency of BRAFV600E mutation was significantly lower in PTC with coexistence HT (48.2%) compared by PTC without HT (62.9%, p=0.004). However, there was no significant difference in clinicopathological feature of PTC according to the presence of HT in patients with BRAFV600E mutated PTC. BRAFV600E mutation was less frequent in PTC with coexistence HT. Conclusion: These findings suggested that HT and BRAFV600E mutation might be independent factors in development and progression of PTC.
Abstract
Background and Objectives: The relationship between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) is still controversial. Some studies suggested that molecular basis of the association between HT and PTC. BRAFV600E mutation is the most common genetic alteration founded in PTC. This study was to determine a role of BRAFV600E mutation in PTC with concurrent HT and their association with other clinicopathological factors. Materials and Methods: We enrolled 452 patients who underwent thyroid surgery between 2009 and 2012 for classical PTC. The status of BRAFV600E mutation was evaluated by direct sequencing. HT was defined as presence of lymphocytic thyroiditis in pathology or positive serum anti-thyroid peroxidase antibody. Results: Total 139 patients (30%) with PTC had coexistence HT. HT was significantly associated female (p=0.006), and younger age (p=0.045). BRAFV600E mutation was confirmed in 264 patients (58%). The frequency of BRAFV600E mutation was significantly lower in PTC with coexistence HT (48.2%) compared by PTC without HT (62.9%, p=0.004). However, there was no significant difference in clinicopathological feature of PTC according to the presence of HT in patients with BRAFV600E mutated PTC. BRAFV600E mutation was less frequent in PTC with coexistence HT. Conclusion: These findings suggested that HT and BRAFV600E mutation might be independent factors in development and progression of PTC.
참고문헌 (30)
- Kilfoy BA, "International patterns and trends in thyroid cancer incidence, 1973-2002", Cancer Causes Control, 20(5), pp.525~531 (2009)
- 안화영, "우리나라 갑상선암의 발생 현황 및 특징", 대한내과학회지, 77(5), pp.537~542 (2009), 대한내과학회
- DeGroot LJ, "Natural history, treatment, and course of papillary thyroid carcinoma", J Clin Endocrinol Metab, 71(2), pp.414~424 (1990)
- Staii A, "Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state", Thyroid Res, 3(1), pp.11~ (2010)
- Jankovic B, "Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation", J Clin Endocrinol Metab, 98(2), pp.474~482 (2013)
- Lee JH, "The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis", Eur J Endocrinol, 168(3), pp.343~349 (2013)
- Prasad ML, "Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC", Histopathology, 45(1), pp.39~46 (2004)
- Di Pasquale M, "Pathologic features of Hashimoto's-associated papillary thyroid carcinomas", Hum Pathol, 32(1), pp.24~30 (2001)
- Unger P, "Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link", Hum Pathol, 34(8), pp.764~769 (2003)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417(6892), pp.949~954 (2002)
- Xing M, "Association between BRAF V600E mutation and recurrence of papillary thyroid cancer", J Clin Oncol, 33(1), pp.42~50 (2015)
- Nucera C, "Targeting thyroid cancer microenvironment: basic research and clinical applications", Front Endocrinol (Lausanne), 4, pp.167~ (2013)
- Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma", Clin Endocrinol (Oxf), 65(3), pp.364~368 (2006)
- Kim KH, "Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis", Pathol Int, 55(9), pp.540~545 (2005)
- Kim EY, "Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma", Clin Endocrinol (Oxf), 71(4), pp.581~586 (2009)
- Choi YM, "Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women", Thyroid, 24(4), pp.655~661 (2014)
- Lee HJ, "Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system", Am J Clin Pathol, 133(5), pp.802~808 (2010)
- Ng WY, "Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis", Thyroid, 14(3), pp.187~190 (2004)
- Singh B, "Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome", Surgery, 126(6), pp.1070~1076 (1999)
- Zhang L, "The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease", BMC Cancer, 12, pp.610~ (2012)
- Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144(5), pp.646~674 (2011)
- McLeod DS, "Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis", J Clin Endocrinol Metab, 97(8), pp.2682~2692 (2012)
- Powell DJ Jr, "The RET", PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids, 1998, pp.58(23), 5523~5528
- Knauf JA, "Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling", Oncogene, 30(28), pp.3153~3162 (2011)
- Knauf JA, "Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation", Cancer Res, 65(10), pp.4238~4245 (2005)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis", Cancer, 110(1), pp.38~46 (2007)
- Marotta V, "BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present", Clin Endocrinol (Oxf), 79(5), pp.733~738 (2013)
- Kim SK, "Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis", Thyroid, 19(2), pp.137~141 (2009)
- Lun Y, "Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis", Otolaryngol Head Neck Surg, 148(3), pp.396~402 (2013)
- Guerra A, "A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome", J Clin Endocrinol Metab, 97(7), pp.2333~2340 (2012)